Illumina, Inc. (NASDAQ:ILMN) Shares Acquired by Gryphon Financial Partners LLC

Gryphon Financial Partners LLC increased its stake in Illumina, Inc. (NASDAQ:ILMNFree Report) by 22.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,807 shares of the life sciences company’s stock after acquiring an additional 327 shares during the quarter. Gryphon Financial Partners LLC’s holdings in Illumina were worth $252,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Illumina during the third quarter valued at $30,000. VisionPoint Advisory Group LLC grew its holdings in shares of Illumina by 344.6% during the third quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after buying an additional 193 shares in the last quarter. Wetzel Investment Advisors Inc. purchased a new position in shares of Illumina during the fourth quarter valued at $37,000. Gradient Investments LLC grew its holdings in shares of Illumina by 375.0% during the fourth quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after buying an additional 225 shares in the last quarter. Finally, North Star Investment Management Corp. grew its holdings in shares of Illumina by 183.0% during the fourth quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after buying an additional 194 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $104.28 on Monday. The business has a 50 day moving average price of $119.61 and a 200 day moving average price of $126.94. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $213.12. The company has a market cap of $16.61 billion, a price-to-earnings ratio of -12.80 and a beta of 1.20. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMNGet Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.04 by $0.05. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.08 EPS. Research analysts predict that Illumina, Inc. will post 0.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on ILMN. OTR Global restated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Stephens restated an “overweight” rating and issued a $170.00 target price on shares of Illumina in a research note on Tuesday, May 7th. Scotiabank lowered their target price on Illumina from $185.00 to $176.00 and set a “sector outperform” rating on the stock in a research note on Monday, May 6th. Royal Bank of Canada restated an “outperform” rating and issued a $253.00 target price on shares of Illumina in a research note on Tuesday, April 9th. Finally, Robert W. Baird boosted their target price on Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Illumina presently has an average rating of “Hold” and an average target price of $164.65.

Read Our Latest Stock Analysis on Illumina

About Illumina

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Read More

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.